成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

化合物 TAK632,TAK-632

化合物 TAK632|T1886|TargetMol

價格 ￥326 ￥541 ￥827
包裝 2mg 5mg 10mg
最小起訂量 1mg
發(fā)貨地 上海
更新日期 2024-12-12
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:化合物 TAK632英文名稱:TAK-632
CAS:1228591-30-7品牌: TargetMol
產(chǎn)地: 美國保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
純度規(guī)格: 98.92%產(chǎn)品類別: 抑制劑
貨號: T1886
2024-12-12 化合物 TAK632 TAK-632 2mg/326RMB;5mg/541RMB;10mg/827RMB 326 TargetMol 美國 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. 98.92% 抑制劑

Product Introduction

Bioactivity

名稱TAK-632
描述TAK-632 is a potent pan-Raf inhibitor.
細(xì)胞實驗The cells are proliferated in appropriate medium (vender recommended) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics, in tissue culture dishes placed in a humidified incubator maintained at 37°C in an atmosphere of 5% CO2 and 95% air. The anti-proliferative activity of compound is determined by treating cell lines with the compound for 3 days, followed by measurement of viable cell number in the Cell Titer-Glo assay. The cells are seeded in a 96-multiwell plate at 1500 to 4000 cells per well in medium containing FBS and cells allowed to sit down overnight. After 18–20 h, compounds at various concentrations by serial dilution are added to the cells and were cultured for 3 days in chamber. After the treatment culture, cellular proliferation is determined by a Cell Titer-Glo Luminescent Cell Viability Assay. In brief, 100 bL/well of Cell Titer-Glo Substrate solution is added to each well and the cells were cultured for an additional 10 minutes (approximately). The chemi-luminescence value is measured using a Luminescence Counter 1420 ARVO MX Light. Concentration response curves are generated by calculating the decrease in chemi-luminescence values in compound-treated samples relative to the vehicle (DMSO) treated controls. (Only for Reference)
激酶實驗Kinase Profile Assay: Assays for serine/threonine kinases using radio labeled [γ-33P] ATP are performed in 96 well plates. BRAF and c-RAF are expressed as N-terminal FLAG-tagged protein using a baculovirus expression system. The reaction conditions are optimized for each kinase: BRAF (25 ng/well of enzyme, 1 μg/well of GST-MEK1(K96R), 0.1 μCi/well of [γ-32P] ATP, room temperature, 20 min reaction); c-RAF (25 ng/well of enzyme, 1 μg/well of GST-MEK1 (K96R), 0.1 μCi/well of [γ-32P] ATP, room temperature, 20 min reaction). Enzyme reactions are performed in 25 mM HEPES, pH 7.5, 10 mM magnesium acetate, 1 mM dithiothreitol and 0.5 μM ATP containing optimized concentration of enzyme, substrate and radiolabeled ATP as described above in a total volume of 50 μL. Prior to the kinase reaction, compound and enzyme are incubated for 5 min at reaction temperature as described above. The kinase reactions are initiated by adding ATP. After the reaction period as described above, the reactions are terminated by the addition of 10% (final concentration) trichloroacetic acid. The [γ-33P] or [γ-32P]-phosphorylated proteins are filtered in GFC filter plates with a Cell Harvester and then the plates are washed out with 3% phosphoric acid. The plates are dried, followed by the addition of 40 μL of MicroScint0. The radioactivity is counted by a TopCount scintillation counter.
體外活性在攜帶NRAS突變型黑素瘤的SK-MEL-2異種移植小鼠模型中,口服 TAK-632（60 or 120 mg/kg）抑制 MAPK 信號通路,抑制腫瘤的發(fā)展.
體內(nèi)活性在A375（GI50=66 nM）和HMVII系（和GI50=200 nM）中,TAK-632能夠抑制細(xì)胞增殖。其中,在黑色素瘤A375細(xì)胞系(BRAFV600E)中,TAK-632抑制MEK（IC50=2 nM）和ERK磷酸化（IC50=16 nM）。在人類黑色素瘤HMVII細(xì)胞系(NRASQ61K/BRAFG469V)中,TAK-632抑制pMEK（IC50=49 nM）和pERK（IC50=50 nM）。
存儲條件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 93 mg/mL (167.7 mM)
Ethanol : 2 mg/mL (3.6 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字inhibit | Inhibitor | TAK632 | Raf kinases | TAK-632 | Raf | Aurora Kinase | TAK 632
相關(guān)產(chǎn)品Imatinib | Amlexanox | Dabrafenib | Formononetin | Axitinib | Lenvatinib mesylate | Ferulic Acid | Regorafenib | Pazopanib | Nintedanib | Sorafenib | Regorafenib monohydrate
相關(guān)庫抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | 抗肥胖化合物庫 | 膜蛋白靶向化合物庫 | 疼痛相關(guān)化合物庫 | 酪氨酸激酶分子庫
關(guān)鍵字： TAK-632|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。 憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。
成立日期 2013-04-18 （12年） 注冊資本 566.265100萬人民幣
員工人數(shù) 100-500人 年營業(yè)額 ￥ 1億以上
主營行業(yè) 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) 經(jīng)營模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • TargetMol中國（陶術(shù)生物）
VIP 3年
  • 公司成立：12年
  • 注冊資本：566.265100萬人民幣
  • 企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
  • 主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
  • 公司地址：靜安區(qū)江場三路238號8樓
詢盤

化合物 TAK632|T1886|TargetMol相關(guān)廠家報價

產(chǎn)品名稱 價格   公司名稱 報價日期
詢價
VIP1年
青島愷潤生物醫(yī)藥科技有限公司
 2025-02-07
詢價
VIP5年
山東沃德森生物科技有限公司
 2025-02-12
詢價
VIP2年
陜西西化化學(xué)工業(yè)有限公司
 2025-02-19
詢價
VIP6年
上海澤葉生物科技有限公司
 2025-02-26
￥504.90
VIP2年
上海阿拉丁生化科技股份有限公司
 2024-11-29
內(nèi)容聲明:
以上所展示的信息由商家自行提供，內(nèi)容的真實性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價格指該商品的參考價格，并非原價，該價格可能隨著市場變化，或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價格，請咨詢商家，以實際成交價格為準(zhǔn)。請意識到互聯(lián)網(wǎng)交易中的風(fēng)險是客觀存在的